Clinical research and pharmacology service provider Celerion has appointed Dr Marc Hoffman as chief medical officer.
Dr Hoffman joins Celerion from Patient Identification Platform, where he also served as chief medical officer, overseeing the firm’s platform and programmes.
He brings further experience from Theorem Clinical Research, where he was chief medical officer, senior vice president and general manager.
Previously, Dr Hoffman served as vice president of medical and scientific affairs at Covance and vice president of global medical affairs and product safety at Hospira.
He also brings experience as vice president for global regulatory affairs and medical vigilance for Baxter’s operations in Asia and the Americas.
Dr Susan Thornton, president and chief executive officer of Celerion, said: “We are pleased to have Marc join our executive leadership team during this exciting period of growth in our company.
“His depth of experience in managing all aspects of global drug development in multiple therapeutic areas will not only make him a valuable asset for our organization but also for our clients.”